Moteur de recherche d’entreprises européennes
Financement de l’UE (3 759 490 €) : IMAGERIE DE NOUVELLE GÉNÉRATION POUR LA VÉRIFICATION DE LA DOSE EN TEMPS RÉEL PERMETTANT LA PROTONTHÉRAPIE ADAPTATIVE Hor06/12/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
IMAGERIE DE NOUVELLE GÉNÉRATION POUR LA VÉRIFICATION DE LA DOSE EN TEMPS RÉEL PERMETTANT LA PROTONTHÉRAPIE ADAPTATIVE
The NOVO project will address a fundamental issue in proton radiotherapy (PT) of cancer, namely the lack of real-time dose verification (RDV) that significantly limits the potential of PT due to uncertainties in the precise delivery of the prescribed dose. In the NOVO project, we will develop the first proof-of-concept of an RDV technology adaptable to any PT treatment and bring the concept to TRL 4 by also considering integration into the PT clinical workflow. The RDV technology will be pivotal for enabling the next generation of adaptive PT therapy, i.e., dose-guided real-time adaptive therapy. Real-time measurement of the dose to targeted and non-targeted tissues will be the key to truly empower patient-centered, personalized cancer treatment, important to improve curation and quality-of-life post-treatment. As a high-risk/high-gain project, NOVO aims at a first-of-its-kind RDV technology through the unique synergy between (1) cutting-edge, inexpensive organic scintillator technology that can detect secondary radiation during treatment for non-invasive measurements, (2) novel and fast image reconstruction, artificial intelligence (AI)-accelerated models and AI-enhanced image reconstruction to allow simultaneous detection of multiple radiation species and tissue compositional analysis, (3) tumor-tracking and imaging of tissue radio-sensitivity based on oxygen levels, (4) intelligent automation of decision-making schemes for real-time dose-guided adaptive therapy. The project will essentially open a new era in PT that enables curing more cancer patients and reducing toxicity from treatment. The NOVO consortium covers the entire value chain of RDV development (technology providers, theory and modelling, technology integration and PT clinics) and optimally engages nuclear, medical, and high-energy physicists, chemists, mathematicians, computer scientists, oncologists, biologists, as well as European PT centers.
| The University of Manchester | ? |
| Bogazici Universitesi | 729 375 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 496 255 € |
| HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF e. V. | 711 000 € |
| Helse Bergen HF | 508 656 € |
| Hogskulen PA Vestlandet | 661 599 € |
| TARGET SYSTEMELEKTRONIK GmbH & Co.KG | 266 438 € |
| Universitetet I Bergen | 386 167 € |
https://cordis.europa.eu/project/id/101130979
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : The University of Manchester, Manchester, Royaume Uni.
